Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
The Health Care Select Sector SPDR Premium Income Fund (XLVI) belongs to the Options Strategies segment. VanEck Biotech ETF (BBH) is part of the US Health Care segment. Both ETFs have the same top 3 sector exposures: and Health Care. Both XLVI and BBH have the same Total Expense Ratio (TER) of 0.35%. XLVI is up 0.28% year-to-date (YTD) with +$2M in YTD flows. BBH performs better with 1.49% YTD performance, and -$2M in YTD flows. Run a side-by-side ETF comparison of XLVI and BBH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XLVI BBH | -1.07%-1.90% | +1.89%+0.58% | +0.28%+1.49% | n/a+19.17% | n/a+25.33% | n/a+12.69% |
| Flows | XLVI BBH | +$788K-$2M | +$3M-$2M | +$2M-$2M | --$58M | --$190M | --$121M |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XLVI BBH | +10.15%+19.85% | n/a+22.37% | n/a+18.42% | n/a+21.47% |
| Max drawdown | XLVI BBH | -3.26%-6.07% | n/a-14.98% | n/a-22.78% | n/a-39.88% |
| Max drawdown duration | XLVI BBH | 10d43d | n/a128d | n/a440d | n/a1675d |
XLVI | BBH | |
Last sale 3/11/2026 at 7:59 PM | $25.92 | $188.44 |
| Previous close 03/11/2026 | $25.98 | $192.04 |
| Consolidated volume 03/11/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
XLVI | BBH | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
XLVI | BBH | |
|---|---|---|
| Last price | $25.92 | $188.44 |
| 1D performance | -0.23% | -1.87% |
| AuM | $13.24 M | $379.50 M |
| E/R | 0.35% | 0.35% |
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
